Thugmuffin
2 년 전
$BSEM BioStem Technologies® CEO to Appear on the Benzinga All Access Show on June 17,2022Press Release | 06/17/2022
POMPANO BEACH, FLORIDA, June 17, 2022 (GLOBE NEWSWIRE) -- BioStem Technologies® (OTC: BSEM), a leading, innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies will be hosted on Benzinga’s All Access show, which airs on Benzinga TV and Benzinga’s YouTube channel on June 17 2022, at 10:20 AM EST.
BioStem Technologies CEO Jason Matuszewski will be interviewed and provide updates on the latest developments in BioStem’s business growth and portfolio of products. A link to the YouTube broadcast will be available in our investor relations news portal at the below link:
https://www.biostemtechnologies.com/news.
Or watch or listen live to the All-Access broadcast via the Benzinga YouTube channel in the link below:
About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioRetain® processing method. BioRetain has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB®”). These systems and procedures are established per current Good Tissue Practices (“cGTP”) and current Good Manufacturing Processes (“cGMP”). Our portfolio of quality brands includes VENDAJE®, VENDAJE® AC, and VENDAJE® OPTIC. Each BioStem Technologies placental allograft is processed at the Company’s FDA registered and AATB accredited site in Pompano Beach, Florida.
Investor Relations:
info@biostemtech.com
(954) 380-8342
AskMuncher
3 년 전
$BSEM BioStem Technologies, Inc. Awarded Q Code for VENDAJE® Product Line From CMS.
Press Release | 07/23/2021
Pompano Beach, Fl., July 23, 2021 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) ("BioStem" or the "Company"), a pre-clinical-stage biotechnology company focused on harnessing elements of perinatal tissue for use in regenerative therapies; announces that the Centers for Medicare and Medicaid Services (“CMS”) has published a new code pursuant to the Company’s application for Healthcare Common Procedure Coding System (“HCPCS”) “Q” codes. The Company initially filed an application in July of 2020 to have CMS establish a new HCPCS Q code for VENDAJE® and has now received a favorable decision in July of 2021.
The HCPCS Q-code assigned to VENDAJE will be billed as Q4252, and will be effective October 1st, 2021. Q-Codes are established to identify drugs, biologicals, and medical equipment or services not identified by national HCPCS Level II codes, but for which codes are needed for Medicare claims processing. CMS, via its sub-committee, the HCPCS Committee, assigns Q-Codes based on the Committee's review and they are maintained by the HCPCS national panel, which is comprised of representatives from the Health Insurance Association of America, Blue Cross/Blue Shield, and CMS.
Jason Matuszewski, CEO of BioStem Technologies, states, "Establishment of a unique Q-code for VENDAJE is an integral building block to our growth and reimbursement strategy and will offer greater access to our tissue allografts for patients and providers through Medicare and the CMS system. We are excited about the opportunities that this new Q-code provides for our customers to now more appropriately bill and code for VENDAJE and we anticipate significant growth opportunities. We will continue to work to ensure we can deliver better outcomes that improve quality of life, reduce recovery times, and lower costs.”
About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies, Inc. is a pre-clinical-stage biotechnology company focused on harnessing elements of perinatal tissue and the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Our proprietary approach, called Local Microenvironment Activation®, or LMA®, uses combinations of small molecules, cytokines, and growth factors to activate the microenvironment within the body to create communication for repair in the tissue. BioStem Technologies offers a comprehensive portfolio of high-quality brands that include RHEO™, OROPRO®, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. The Company is comprised of a diverse group of scientists, physicians, and entrepreneurs who collaborate to create innovative products. These technologies improve the Quality of Life for our patients and, as a result, drive shareholder value.
Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.
BioStem Technologies, Inc.
Phone: 954-380-8342
Website: http://www.biostemtechnologies.com
Email: info@biostemtech.com
Twitter: @BSEM_Tech
Facebook: BioStem Technologies
Investor Relations:
info@biostemtech.com
(954) 380-8342
AskMuncher
4 년 전
$BSEM BioStem Technologies, Inc. Announces Launch of National Sales Force Expansion
Press Release | 04/15/2021
Pompano Beach, Fl., April 15, 2021 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) ("BioStem" or the "Company"), a pre-clinical-stage biotechnology company focused on harnessing elements of perinatal tissue for use in regenerative therapies, today announced the launch of a national sales force expansion. The expansion aims to increase the number of dedicated regional sales representatives actively selling the Company’s perinatal tissue allografts.
As the economy reopens from blanket shutdowns related to COVID-19 prevention, treatment facilities are resuming elective surgeries and regenerative therapies. The Company plans to capitalize on the growing demand for high quality perinatal tissue allografts, precipitated by the booming return of these medical procedures.
BioStem will be hiring experienced sales representatives with technical knowledge and business competencies in the orthopedic, wound care and urology verticals.
The regional focus of the expansion will concentrate on three regions, North East (with states such as New York, Pennsylvania, Connecticut, and New Jersey), Midwest (with states such as Illinois, Ohio, Minnesota and Wisconsin) and the Mountain Region (with states such as Nevada, Arizona, Colorado, Utah, New Mexico, Montana and Wyoming).
Qualified sales representatives who may be interested are asked to visit www.biostemtechnologies.com/agents and fill out the contact form to receive more information.
About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies, Inc. is a pre-clinical-stage biotechnology company focused on harnessing elements of Perinatal Tissue and the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Our proprietary approach, called Local Microenvironment Activation, or LMA, uses combinations of Small Molecules, Cytokines, and Growth Factors to activate the microenvironment within the body to create communication for repair in the tissue. BioStem Technologies offers a comprehensive portfolio of high-quality brands that include RHEO™, OROPRO™, AEON™, VENDAJE™, VENDAJE™ AC, and VENDAJE™ OPTIC. The Company is comprised of a diverse group of scientists, physicians, and entrepreneurs who collaborate to create innovative products. These technologies improve the Quality of Life for our patients and, as a result, drive shareholder value.
Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.
BioStem Technologies, Inc.
Phone: 954-380-8342
Website: http://www.biostemtechnologies.com
Email: info@biostemtech.com
Twitter: @BSEM_Tech
Facebook: BioStem Technologies
Investor Relations:
info@biostemtech.com
(954) 380-8342
AskMuncher
4 년 전
$BSEM BioStem Technologies Engages D. Brooks & Associates for 2020 and 2019 Audit
Press Release | 03/15/2021
Pompano Beach, Fl., March 15, 2021 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) ("BioStem" or the "Company"), a leading pre-clinical-stage biotechnology company focused on harnessing elements of Perinatal Tissue for use in regenerative therapies, today announced it engaged D. Brooks and Associates CPA's, P.A. as the Company’s PCAOB registered certified public accounting firm for the 2020 and 2019 fiscal years.
We expect the audit to be complete sometime in the second quarter of 2021. Upon completion of the audit, BioStem intends to examine the possibility of becoming fully reporting with the SEC.
BioStem 's CEO, Jason Matuszewski, said, "We believe this is the appropriate time to hire a PCAOB auditor, as it aligns with our capital markets and reporting company goals.”
About D. Brooks and Associates CPA's, P.A. Headquartered in West Palm Beach, Florida, D. Brooks and Associates CPA's, P.A. is a PCAOB registered certified public accounting firm that offers clients professional and courteous attention while delivering practical value in addressing their needs. We have extensive experience in assisting clients with highly complex issues as well as day to day operational needs. Our principals are native residents of South Florida and share a passion for helping businesses and individuals achieve success in financial matters. The Firm's philosophy is to provide clients National level technical expertise through hands on relationships that emphasize understanding client issues, addressing them with appropriate urgency, and maintaining effective communications so as to maximize value delivered as a result of these relationships.
About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies, Inc. is a pre-clinical-stage biotechnology company focused on harnessing elements of Perinatal Tissue and the bodys innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Our proprietary approach, called Local MicroEnvironment Activation, or LMA, uses combinations of Small Molecules, Cytokines, and Growth Factors to activate the microenvironment within the body to create communication for repair in the tissue. BioStem Technologies offers a comprehensive portfolio of high-quality brands that include RHEO™, OROPRO™, AEON™, VENDAJE™, VENDAJE™ AC, and VENDAJE™ OPTIC. BioStem's flowable and membrane-based amniotic allografts are all processed in the Company’s own FDA registered and AATB® accredited lab located in Pompano Beach, Florida. The company is comprised of a diverse group of scientists, physicians, and entrepreneurs who collaborate to create innovative products. These technologies improve the Quality of Life for our patients and, as a result, drive shareholder value.
Qualified sales representatives and distributors who are actively looking to sell regenerative biologics to clinics and hospitals are asked to visit www.biostemtechnologies.com and fill out the contact form to receive more information.
Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.
BioStem Technologies, Inc.
Phone: 954-380-8342
Website: http://www.biostemtechnologies.com
Email: info@biostemtech.com
Twitter: @Biostemtech
Facebook: BioStem Technologies
Investor Relations:
info@biostemtech.com
(954) 380-8342
AskMuncher
4 년 전
$BSEM BioStem Technologies, Announces Filing of 2020 Quarterly Reports
Press Release | 12/24/2020
Pompano Beach, Fl, Dec. 24, 2020 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) ("BioStem" or the "Company"), a leading life sciences company specializing in perinatal tissue allografts for use in regenerative therapies, today announced that it has filed its quarterly reports for 2020 to become current with OTC Markets.
BioStem's Chief Executive Officer, Jason Matuszewski, commented, "The filing of our 2020 quarterly reports not only marks a key milestone for BioStem, but also reflects the level of transparency we strive to achieve for our shareholders. Current financial reporting, along with increased and timely dialogue, are a top priority. We also continue to take actions that focus on improving the lives of patients and their families, provide business resiliency, and restore the Company’s financial integrity and reputation. We feel confident we can maintain current status with our reporting requirements for OTC Markets with the addition of our key financial team members; we are moving forward!”
About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies, Inc. is a global life sciences corporation, providing innovative technologies with a concentration in Regenerative Medicine. The company's mission is to discover, develop and produce the most effective Regenerative Medicine products in the world. BioStem Technologies offers a comprehensive portfolio of high-quality brands that include AEON™, RHEO™, OROPRO™, VENDAJE™, VENDAJE™ AC and VENDAJE™ OPTIC. The company is comprised of a diverse group of scientists, physicians, and entrepreneurs who collaborate to create innovative products. These technologies improve the Quality of Life for our patients and, as a result, drive shareholder value. For the latest news and information about BioStem Technologies and its brands, please visit www.biostemtechnologies.com
Forward-Looking Statements: Except for historical fact statements, the matters discussed in this press release are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition, and additional risks factors as discussed in reports filed by the company with OTC Markets.
?
BioStem Technologies, Inc.
Phone: 954-380-8342
Website: http://www.biostemtechnologies.com
Email: info@biostemtech.com
Twitter: @BSEM_Tech
Facebook: https://www.facebook.com/biostemtechnologies/
Investor Relations:
info@biostemtech.com
(954) 380-8342
Primary Logo
AskMuncher
4 년 전
$BSEM ioStem Technologies, Announces Filing of 2020 Quarterly Reports
Press Release | 12/24/2020
Pompano Beach, Fl, Dec. 24, 2020 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) ("BioStem" or the "Company"), a leading life sciences company specializing in perinatal tissue allografts for use in regenerative therapies, today announced that it has filed its quarterly reports for 2020 to become current with OTC Markets.
BioStem's Chief Executive Officer, Jason Matuszewski, commented, "The filing of our 2020 quarterly reports not only marks a key milestone for BioStem, but also reflects the level of transparency we strive to achieve for our shareholders. Current financial reporting, along with increased and timely dialogue, are a top priority. We also continue to take actions that focus on improving the lives of patients and their families, provide business resiliency, and restore the Company’s financial integrity and reputation. We feel confident we can maintain current status with our reporting requirements for OTC Markets with the addition of our key financial team members; we are moving forward!”
About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies, Inc. is a global life sciences corporation, providing innovative technologies with a concentration in Regenerative Medicine. The company's mission is to discover, develop and produce the most effective Regenerative Medicine products in the world. BioStem Technologies offers a comprehensive portfolio of high-quality brands that include AEON™, RHEO™, OROPRO™, VENDAJE™, VENDAJE™ AC and VENDAJE™ OPTIC. The company is comprised of a diverse group of scientists, physicians, and entrepreneurs who collaborate to create innovative products. These technologies improve the Quality of Life for our patients and, as a result, drive shareholder value. For the latest news and information about BioStem Technologies and its brands, please visit www.biostemtechnologies.com
Forward-Looking Statements: Except for historical fact statements, the matters discussed in this press release are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition, and additional risks factors as discussed in reports filed by the company with OTC Markets.
?
BioStem Technologies, Inc.
Phone: 954-380-8342
Website: http://www.biostemtechnologies.com
Email: info@biostemtech.com
Twitter: @BSEM_Tech
Facebook: https://www.facebook.com/biostemtechnologies/
Investor Relations:
info@biostemtech.com
(954) 380-8342
AskMuncher
4 년 전
$BSEM BioStem Life Sciences Receives Accreditation by The American Association of Tissue Banks® (AATB®)
Press Release | 07/15/2020
Pompano Beach, FL, July 15, 2020 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) a leading life sciences company specializing in the development and sale of perinatal tissue-based allografts for use in regenerative therapies, today announced that its subsidiary, BioStem Life Sciences has been awarded the prestigious accolade of accreditation by the American Association of Tissue Banks® (AATB®). BioStem Life Sciences is now accredited for Donor Eligibility Assessment, Processing, Storage, and Distribution of Birth Tissue and Cellular Tissue for Transplantation.
This accreditation follows an intensive review and auditing process, including a thorough on-site inspection by experienced AATB® personnel, of both the facility itself, and all of the associated documentation and practices. Accreditation establishes that the level of medical, technical, and administrative performance within the facility meets or exceeds the standards set by the AATB®.
Obtaining AATB® accreditation demonstrates an organization's commitment to the highest standards and the utmost level of service to patients and the tissue-banking community as a whole. Accredited organizations are recognized as the leaders in the space and as influential voices in the dialogue through which consensus-based, voluntary standards are developed and implemented.
"The American Association of Tissue Banks® accreditation is another significant milestone for BioStem Life Sciences (BSLS) and our CDMO partners. BioStem Life Sciences is dedicated to Good Stewardship of Tissue, providing the highest quality product on the market, improving both the health, recovery and quality of life of transplant recipients. We are proud that the AATB® recognizes that our products and services reflect the highest level of quality and control,” commented Andrew Van Vurst, COO. “We strive to provide the highest quality of off-the-shelf biologics and CDMO services to our clients."
Thomas Sutera, Director of Quality, said “We are extremely proud of the hard work and dedication that our staff has put in to ensuring we build and maintain the levels of quality and efficiency that place us at the top of our industry.”
About BioStem Life Sciences, Inc. A company focused on the development of the highest quality birth tissue products for multiple sectors of healthcare. BioStem Life Sciences also provides leading class contract development and manufacturing services to GMP and GTP standards for companies looking to develop birth tissue products, from bench top to commercialization. For the latest news and information about BioStem Life Sciences and its brands, please visit www.biostemlifesciences.com
About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies, Inc. is a global life sciences corporation, providing innovative technologies with a concentration in Regenerative Medicine. The company’s mission is to discover, develop and produce the most effective Regenerative Medicine products in the world. BioStem Technologies offers a comprehensive portfolio of high-quality brands that include RHEO™, OROPRO™, VENDAJE™, VENDAJE™ AC and VENDAJE™ OPTIC. The company is comprised of a diverse group of scientists, physicians, and entrepreneurs who collaborate to create innovative products. These technologies improve the Quality of Life for our patients and, as a result, drive shareholder value.
Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.
BioStem Technologies, Inc.
Phone: 954-380-8342
Website: http://www.biostemtechnologies.com
Email: info@biostemtech.com
Twitter: @Biostemtech
Facebook: BioStem Technologies
Investor Relations:
info@biostemtech.com
(954) 380-8342
AskMuncher
4 년 전
$BSEM BioStem Technologies, Inc. Announces Submission of Applications for Q-Codes from the Centers for Medicare and Medicaid Services (CMS)
Press Release | 07/02/2020
Pompano Beach, FL, July 02, 2020 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM), a leading life sciences company specializing in the development and commercialization of perinatal tissue-based allografts for regenerative therapies, today announced the submission of applications for three of its dehydrated placental membrane allograft products to the Centers for Medicare and Medicaid Services (CMS), in process to be granted Q-Codes.
Q-Codes are established to identify drugs, biologicals, and medical equipment or services not identified by national HCPCS Level II codes, but for which codes are needed for Medicare claims processing. The Centers for Medicare and Medicaid Services (CMS), via its sub-committee, the Healthcare Common Procedure Coding System (HCPCS) Committee, assigns Q-Codes based on the Committee's review and they are maintained by the HCPCS national panel, which is comprised of representatives from the Health Insurance Association of America, Blue Cross/Blue Shield, and CMS.
The committee will review the applications and make a decision in November of 2020. If approved, the Company’s products VENDAJE™, VENDAJE™ AC, and VENDAJE™ OPTIC will obtain Q-Codes to be active on January 1st, 2021.
“These Q-Codes are the strategic next step for BioStem in the reimbursement process. By making these products eligible for Medicare coverage and reimbursement, the beneficiaries will be able to receive the treatments they need at a cost they can afford.” said CEO, Jason Matuszewski.
The global Tissue Engineered Skin Substitutes market in 2020 is valued at $131.5 billion and is anticipated to $335.5 billion by 2025 growing at an estimated value of CAGR of more than 16.9% during the forecast period 2020 to 2025. North America will dominate the Tissue Engineered Skin Substitutes Market in the upcoming years. It will generate revenue of $169.4 billion by 2025 at a CAGR of 16.70%.1
About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies, Inc. is a global life sciences corporation, providing innovative technologies with a concentration in Regenerative Medicine. The company’s mission is to discover, develop and produce the most effective Regenerative Medicine products in the world. BioStem Technologies offers a comprehensive portfolio of high-quality brands that include RHEO™, VENDAJE™, VENDAJE™ AC, and VENDAJE™ OPTIC. The company is comprised of a diverse group of scientists, physicians, and entrepreneurs who collaborate to create innovative products. These technologies improve the Quality of Life for our patients and, as a result, drive shareholder value.
Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.
AskMuncher
4 년 전
$BSEM BioStem Technologies, Inc. Announces Tissue Bank Certification in California and Maryland
Press Release | 06/26/2020
Pompano Beach, FL, June 26, 2020 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) ("BioStem" or the "Company") a leading life sciences company specializing in perinatal tissue-based allografts for use in regenerative therapies, today announced that its subsidiary, BioStem Life Sciences, has added California and Maryland to its list of tissue bank licenses issued by the individual state’s Department of Health.
"This is a significant achievement in the ongoing growth of BioStem Life Sciences. The addition of California and Maryland completes all the required states for tissue bank registration. With these two State licenses it will allow our customers access to distribute products to hospitals, clinics and distribution organizations serving these markets," said Jason Matuszewski, BioStem Technologies CEO.
The Company is actively engaging in new CMO/CDMO client opportunities along with sales and distribution of its legacy product lines in all 50 states.
About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies, Inc. is a global life sciences corporation, providing innovative technologies with a concentration in Regenerative Medicine. The company’s mission is to discover, develop and produce the most effective Regenerative Medicine products in the world. BioStem Technologies offers a comprehensive portfolio of high-quality brands that include RHEO™, VENDAJE™, VENDAJE™ AC, and VENDAJE™ OPTIC. The company is comprised of a diverse group of scientists, physicians, and entrepreneurs who collaborate to create innovative products. These technologies improve the Quality of Life for our patients and, as a result, drive shareholder value.
About BioStem Life Sciences, Inc. A company focused on the development of the highest quality birth tissue products for multiple sectors of healthcare. BioStem Life Sciences also provides leading class contract development and manufacturing services to GMP and GTP standards for companies looking to develop birth tissue products, from bench top to commercialization. For the latest news and information about BioStem Life Sciences and its brands, please visit www.biostemlifesciences.com
Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.
BioStem Technologies, Inc.
Phone: 954-380-8342
Website: http://www.biostemtechnologies.com
Email: info@biostemtech.com
Twitter: @Biostemtech
Facebook: BioStem Technologies
Investor Relations:
info@biostemtech.com
(954) 380-8342
Hot Features
프리미엄
무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
QuicKtip
5 월 전
Singhania
7 월 전
mfayman
1 년 전
Cameo Brien
1 년 전
Anita Dump
1 년 전
resx18
2 년 전
help me
3 년 전
Golden Cross
4 년 전
ElementaryValue
4 년 전
MADDSTACKER
4 년 전
conix
6 년 전
N_D_K_Hey
6 년 전
